Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer

…, U Wernery, S Muyldermans, T Lahoutte… - The FASEB …, 2011 - Wiley Online Library
Accurate determination of tumor human epidermal growth factor receptor 2 (HER2)‐status in
breast cancer patients is possible via noninvasive imaging, provided adequate tracers are …

Nanobody-Based Targeting of the Macrophage Mannose Receptor for Effective In Vivo Imaging of Tumor-Associated Macrophages

…, W Waelput, K Breckpot, L Bouwens, T Lahoutte… - Cancer research, 2012 - AACR
Tumor-associated macrophages (TAM) are an important component of the tumor stroma
and exert several tumor-promoting activities. Strongly pro-angiogenic TAMs that reside in …

Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer

…, N Devoogdt, S Muyldermans, T Lahoutte… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Nanobodies are the smallest fully functional antigen-binding antibody fragments possessing
ideal properties as probes for molecular imaging. In this study we labeled the anti–human …

[HTML][HTML] Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody

…, V Caveliers, N Devoogdt, T Lahoutte - Theranostics, 2014 - ncbi.nlm.nih.gov
RIT has become an attractive strategy in cancer treatment, but still faces important drawbacks
due to poor tumor penetration and undesirable pharmacokinetics of the targeting vehicles. …

Bone marrow stromal cell–derived exosomes as communicators in drug resistance in multiple myeloma cells

…, E Van Valckenborgh, T Lahoutte… - Blood, The Journal …, 2014 - ashpublications.org
The interplay between bone marrow stromal cells (BMSCs) and multiple myeloma (MM)
cells performs a crucial role in MM pathogenesis by secreting growth factors, cytokines, and …

Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma

…, J Lamote, V Caveliers, T Lahoutte - Journal of Nuclear …, 2016 - Soc Nuclear Med
Human epidermal growth factor receptor 2 (HER2) status is one of the major tumor characteristics
in breast cancer to guide therapy. Anti-HER2 treatment has clear survival advantages …

Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT

…, H Revets, P De Baetselier, T Lahoutte - Journal of Nuclear …, 2008 - Soc Nuclear Med
Camelidae possess an unusual class of antibodies devoid of light chains. Nanobodies are
intact antigen-binding fragments that are stable, easily generated against different targets, …

SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression

…, A Bossuyt, H Revets, T Lahoutte - Molecular imaging and …, 2008 - Springer
Purpose Overexpression of the epidermal growth factor receptor (EGFR) occurs with high
incidence in various carcinomas. The oncogenic expression of the receptor has been …

Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions

…, V Caveliers, S Muyldermans, T Lahoutte… - Circulation …, 2012 - Am Heart Assoc
Rationale: A noninvasive tool allowing the detection of vulnerable atherosclerotic plaques is
highly needed. By combining nanomolar affinities and fast blood clearance, nanobodies …

[HTML][HTML] Immunogenicity risk profile of nanobodies

…, Y Elkrim, N Devoogdt, V Caveliers, T Lahoutte… - Frontiers in …, 2021 - frontiersin.org
Nanobodies (Nbs), the variable domains of camelid heavy chain-only antibodies, are a
promising class of therapeutics or in vivo imaging reagents entering the clinic. They possess …